RxDoctor Payments DataLook up a doctor →

Rabih Kashouty, MD

Clinical Neurophysiology · Stuart, FLNPI 1487946539

Payments from drug & device makers

$34,050in general payments, 2019–2025

Across 1,020 payments — averaging $33.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$11K
  • Pfizer$6K
  • AbbVie$3K
  • Merz North America, Inc.$1K
  • Biogen$1K
  • UCB, Inc.$904
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$5,00015%
  • Speaking & faculty fees$8,53125%
  • Travel & lodging$1,5445%
  • Food & beverage$18,94856%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca58$10,957
Pfizer40$5,668
AbbVie(2 entities)201$3,341
Merz North America, Inc.13$1,209
Biogen51$1,058
UCB, Inc.43$904
Acadia Pharmaceuticals Inc59$713
Zyla Life Sciences, Inc.82$613
Argenx US, Inc.34$575
Sunovion Pharmaceuticals Inc.33$535
Eisai Inc.17$534
MDD US Operations, LLC28$488
Teva Pharmaceuticals USA, Inc.27$471
Johnson & Johnson(2 entities)15$393
Kyowa Kirin, Inc.18$370
Sanofi20$356
CSL Behring10$338
Supernus Pharmaceuticals, Inc.16$308
SK Life Science, Inc.13$295
Aquestive Therapeutics, Inc.10$293
Revance Therapeutics, Inc.8$258
Galderma Laboratories, L.p.7$250
Neurelis, Inc.15$247
Amgen(2 entities)10$205
Jazz Pharmaceuticals Inc.12$204
Bausch Health US, LLC12$203
Bristol Myers Squibb11$195
Lundbeck LLC10$193
Tanabe Pharma America, Inc.11$188
EMD Serono, Inc.9$175
Livanova USA, Inc.3$170
Greenwich Biosciences, Inc.7$155
Lilly USA, LLC12$155
Biohaven Pharmaceutical Holding Company Ltd.7$141
Amneal Pharmaceuticals LLC9$141
Neurocrine Biosciences, Inc.8$134
Merz Pharmaceuticals, LLC5$123
Novartis6$116
GE HealthCare5$112
Grifols USA, LLC6$104
Biohaven Pharmaceuticals, Inc.5$92
Avanir Pharmaceuticals, Inc.5$88
E.r. Squibb & Sons, L.L.C.4$85
Takeda Pharmaceuticals U.S.A., Inc.4$82
Acorda Therapeutics, Inc4$77
Upsher-smith Laboratories LLC5$68
Microtransponder, Inc.2$61
Arbor Pharmaceuticals, Inc.4$59
Solta Medical, A Division Of Bausch Health US, LLC1$48
Abbott2$47
Genentech USA, Inc.2$40
Alfasigma USA, Inc.2$40
Octapharma USA, Inc.2$39
Avion Pharmaceuticals2$38
Promius Pharma LLC2$36
Idorsia Pharmaceuticals US Inc2$34
Otter Pharmaceuticals, LLC1$33
Sumitomo Pharma America, Inc.2$31
TG Therapeutics, Inc.1$29
Aucta Pharmaceuticals, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$505,015
Medicare patients
433
Services billed
39,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50188$1,257,653
UltomirisRavulizumab-Cwvz24$1,155,902
VyvgartEfgartigimod Alfa-Fcab15$822,455
Gamunex-CImmune Globul G/Gly/Iga Avg 46130$664,648
BotoxOnabotulinumtoxina221$285,227
HizentraImmun Glob G(Igg)/Pro/Iga 0-5025$253,539
PanzygaImmun Glob G(Igg)-Ifas/Glycine13$252,007
Pyridostigmine Bromide29$3,121
Mycophenolate Mofetil11$2,425
Gabapentin59$1,152
Sodium Chloride0.9 % Sodium Chloride52$453
Primidone12$386
Prednisone32$327
Memantine Hcl11$296
Ropinirole Hcl12$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$82$1,257,653188 claims
AstraZenecaUltomiris$10,957$1,155,90224 claims
Argenx US, Inc.Vyvgart$575$822,45515 claims
Grifols USA, LLCGamunex-C$104$664,648130 claims
AbbVieBotox$3,341$285,227221 claims
CSL BehringHizentra$338$253,53925 claims
PfizerPanzyga$5,668$252,00713 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$141$5,54640 claims
Upsher-smith Laboratories LLCTopiramate$68$9123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →